Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

Benzinga Newsdesk www.benzinga.com Positive 71.5%

Neg 0% Neu 0% Pos 71.5%

Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $55 to $57.